Rhone-Poulenc Rorer's performance exceeded the expectations of analysts at Goldman Sachs, who are strongly reiterating their moderate outperformer rating of the company.
First-quarter sales were $1.3 billion, up 8%. Net income was $74 million, an increase of 4% and earnings per share advanced 6% to 55 cents, or 31% after adjustments for gains on asset sales in the first quarter of 1995. Results are restated on a pro forma basis to include the impact of the Centeon joint venture and the acquisitions of Fisons and Applied Immune Sciences (Marketletters passim).
Quarterly sales growth was led by cardiovascular and respiratory products, according to the firm. In the USA, sales advanced 11%, led by antithrombosis agent Clexane/Lovenox (enoxaparin), antiasthmatic agent Azmacort (triamcinolone), and DDAVP (desmopressin), used to treat urinary incontinence. In France, sales were helped by a strong flu season towards the end of 1995, advancing 1.4%. And in the rest of Europe turnover grew 11.5%. Lovenox also performed well in this region, along with Imovane (zopiclone). In Japan, the antacid Maalox had strong sales, as did Albuminar (albumin).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze